Elixir Pharmaceuticals, a Cambridge, Mass., drug discovery company targeting aging, last week named a clinical advisory board that includes Andrew Bodnar, George Daley, Edward Scolnick, and Bennett Shapiro.
Bodnar, who holds MD and JD degrees, is senior vice president, strategy and medical and external affairs, for Bristol-Myers Squibb.
Daley is a venture partner at MPM Capital and chief medical/ scientific advisor to the firm as well as associate professor of biological chemistry and molecular pharmacology and pediatrics, Harvard Medical School, and staff member in hematology/oncology at the Children’s Hospital, Dana Farber Cancer Institute, and Brigham and Women’s Hospital. He holds a PhD in biology from MIT and an MD from Harvard Medical School.
Scolnick is president emeritus of Merck Research Labs and holds BA and MD degrees from Harvard.
Shapiro, now retired, was form-erly senior vice president, worldwide licensing and external scientific affairs at Merck Research Labs. He received an MD from Jefferson Medical College in Philadelphia, and a BA from Dickinson College.
Paul Heaney has joined the scientific advisory board of CalbaTech of Irvine, Calif. Heaney holds a PhD in medicinal chemistry from the University of Glasgow and is a research fellow in DNA sciences with the Imperial Cancer Research Fund, London. He has held research and development positions at Amersham International, Kodak Clinical Diagnostics, Genometrix, Orchid, and Sequenom.
Andre Pernet has been appointed president of Quark Biotech, of Fremont, Calif., which bought Incyte’s microarray business in 2002. Currently, he serves as chairman of CURx Pharma and is on the board of Kaleidos Pharmaceuticals. Between 2000 and 2002, Pernet was chairman and CEO of Genset. Prior to that, he served as corporate officer and vice president, pharmaceutical products R&D, at Abbott Laboratories. Pernet received his Maitrise in science from the Universite de Montpellier, France, and a degree in chemical engineering from Ecole Nationale Superieure de Chimie de Montpellier. He also received a diploma in business management from McGill University and a PhD in chemistry from the University of Montreal.